OBIO TECHNOLOGY (SHANGHAI) CORP., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.65 CNY | -2.11% |
|
-6.06% | -48.28% |
| Sales 2024 * | 255M 35.03M 2.92B | Sales 2025 * | 319M 43.89M 3.66B | Capitalization | 3.01B 414M 34.58B |
|---|---|---|---|---|---|
| Net income 2024 * | -121M -16.65M -1.39B | Net income 2025 * | -36M -4.95M -413M | EV / Sales 2024 * | 11.8 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 9.44 x |
| P/E ratio 2024 * |
-25.1
x | P/E ratio 2025 * |
-87.2
x | Employees | 731 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 63.95% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -2.11% | ||
| 1 week | -6.06% | ||
| Current month | -17.70% | ||
| 1 month | -14.99% | ||
| 3 months | -24.51% | ||
| 6 months | -47.10% | ||
| Current year | -48.28% |
1 week
4.61
5.35
1 month
4.615.73
Current year
4.619.05
1 year
4.6112.32
3 years
4.6127.31
5 years
4.6127.31
10 years
4.6127.31
| Managers | Title | Age | Since |
|---|---|---|---|
Guo Dong Jia
CEO | Chief Executive Officer | 43 | 01/17/01 |
Rui Dong Pan
CHM | Chairman | 56 | 01/13/01 |
Lu Yuan Xu
DFI | Director of Finance/CFO | 54 | 01/16/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Shan Yin
BRD | Director/Board Member | 42 | 01/13/01 |
Gang Wang
BRD | Director/Board Member | 67 | 29/20/29 |
Rui Dong Pan
CHM | Chairman | 56 | 01/13/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25/24/25 | 4.65 | -2.11% | 5,570,991 |
| 24/24/24 | 4.75 | -5.38% | 6,964,171 |
| 21/24/21 | 5.02 | -0.20% | 7,830,050 |
| 20/24/20 | 5.03 | +2.44% | 11,456,150 |
| 19/24/19 | 4.91 | -0.81% | 4,932,856 |
End-of-day quote Shanghai S.E., June 25, 2024
More quotes
OBio Technology Shanghai Corp Ltd is a China-based company mainly engaged in the research and development and production of recombinant viruses for gene therapy. The Company is mainly engaged in providing contract research organization (CRO) services such as gene therapy vector development and gene function research for the basic research of gene therapy, as well as contract research and development production organization (CDMO) services such as pharmaceutical research and clinical sample production for the research and development of gene drugs. The Company mainly conducts business in the European and American markets and the domestic market.
Sector
Pharmaceuticals
Calendar
22/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
4.65
CNY
Average target price
8.2
CNY
Spread / Average Target
+76.34%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -48.28% | 415M | |
| +55.19% | 815B | |
| +47.26% | 654B | |
| -6.09% | 354B | |
| +21.92% | 337B | |
| +18.40% | 247B | |
| +3.64% | 229B | |
| +12.98% | 219B | |
| +10.86% | 171B | |
| -2.78% | 159B |
- Stock Market
- Equities
- 688238 Stock
